You are using an unsupported browser. Please upgrade your browser to a newer version to get the best experience on DrugBank.
Identification
NameNabumetone
Accession NumberDB00461  (APRD01128)
TypeSmall Molecule
GroupsApproved
Description

Nabumetone is a nonsteroidal anti-inflammatory drug (NSAID) of the arylalkanoic acid family (which includes diclofenac). Marketed under the brand name Relafen, it has been shown to have a slightly lower risk of gastrointestinal side effects than most other non-selective NSAIDs.

Structure
Thumb
Synonyms
4-(6-Methoxy-2-naphthalenyl)-2-butanone
4-(6-Methoxy-2-naphthyl)-2-butanone
Nabumeton
Nabumetona
Nabumétone
Nabumetone
Nabumetonum
Relafen
External Identifiers
  • BRL 14777
Approved Prescription Products
NameDosageStrengthRouteLabellerMarketing StartMarketing End
Mylan-nabumetonetablet500 mgoralMylan Pharmaceuticals Ulc2002-02-20Not applicableCanada
Nabumetonetablet500 mgoralSanis Health Inc2010-02-16Not applicableCanada
Nabumetone-500tablet500 mgoralPro Doc Limitee2008-04-072010-07-13Canada
Nu-nabumetonetablet500 mgoralNu Pharm IncNot applicableNot applicableCanada
PMS-nabumetonetablet750 mgoralPharmascience IncNot applicableNot applicableCanada
PMS-nabumetonetablet500 mgoralPharmascience IncNot applicableNot applicableCanada
Relafen Tablets 500mgtablet500 mgoralGlaxosmithkline Inc1994-12-312006-02-13Canada
Relafen Tablets 750mgtablet750 mgoralGlaxosmithkline Inc1998-01-292006-02-13Canada
Sandoz Nabumetonetablet500 mgoralSandoz Canada Incorporated2002-02-212008-08-07Canada
Teva-nabumetonetablet750 mgoralTeva Canada Limited2000-05-18Not applicableCanada
Teva-nabumetonetablet500 mgoralTeva Canada Limited2000-03-08Not applicableCanada
Approved Generic Prescription Products
NameDosageStrengthRouteLabellerMarketing StartMarketing End
Apo-nabumetonetablet500 mgoralApotex Inc1998-08-21Not applicableCanada
Nabumetonetablet500 mg/1oralBlenheim Pharmacal, Inc.2010-03-24Not applicableUs
Nabumetonetablet, film coated500 mg/1oralH.J. Harkins Company, Inc.2008-03-01Not applicableUs
Nabumetonetablet, film coated750 mg/1oralPreferred Pharmaceuticals, Inc.2012-01-30Not applicableUs
Nabumetonetablet500 mg/1oralREMEDYREPACK INC.2011-06-09Not applicableUs
Nabumetonetablet500 mg/1oralAmerican Health Packaging2013-10-28Not applicableUs
Nabumetonetablet, film coated750 mg/1oralDIRECT RX2015-01-01Not applicableUs
Nabumetonetablet, film coated750 mg/1oralBlenheim Pharmacal, Inc.2013-10-08Not applicableUs
Nabumetonetablet, film coated750 mg/1oralNcs Health Care Of Ky, Inc Dba Vangard Labs2008-03-01Not applicableUs
Nabumetonetablet, film coated500 mg/1oralTeva Pharmaceuticals USA Inc2001-08-20Not applicableUs
Nabumetonetablet500 mg/1oralAvera Mc Kennan Hospital2015-03-23Not applicableUs
Nabumetonetablet, film coated500 mg/1oralMedsource Pharmaceuticals2008-03-01Not applicableUs
Nabumetonetablet750 mg/1oralLake Erie Medical DBA Quality Care Products LLC2002-02-25Not applicableUs
Nabumetonetablet, film coated500 mg/1oralClinical Solutions Wholesale2011-06-13Not applicableUs
Nabumetonetablet, film coated500 mg/1oralBlenheim Pharmacal, Inc.2013-05-22Not applicableUs
Nabumetonetablet, film coated750 mg/1oralWatson Laboratories, Inc.2011-06-13Not applicableUs
Nabumetonetablet, film coated750 mg/1oralMedsource Pharmaceuticals2008-03-01Not applicableUs
Nabumetonetablet, film coated750 mg/1oralRx Change Co.2014-11-13Not applicableUs
Nabumetonetablet750 mg/1oralClinical Solutions Wholesale2011-06-13Not applicableUs
Nabumetonetablet, film coated750 mg/1oralNorthwind Pharmaceuticals, LLC2014-10-28Not applicableUs
Nabumetonetablet, film coated500 mg/1oralPreferred Pharmaceuticals, Inc.2012-01-30Not applicableUs
Nabumetonetablet, film coated500 mg/1oralDispensing Solutions, Inc.2008-03-01Not applicableUs
Nabumetonetablet, film coated500 mg/1oralBlenheim Pharmacal, Inc.2010-06-11Not applicableUs
Nabumetonetablet, film coated500 mg/1oralWatson Laboratories, Inc.2011-06-13Not applicableUs
Nabumetonetablet, film coated500 mg/1oralDIRECT RX2015-01-01Not applicableUs
Nabumetonetablet, film coated750 mg/1oralSTAT Rx USA LLC2008-03-01Not applicableUs
Nabumetonetablet, film coated500 mg/1oralRx Change Co.2014-11-13Not applicableUs
Nabumetonetablet500 mg/1oralPd Rx Pharmaceuticals, Inc.2002-02-25Not applicableUs
Nabumetonetablet, film coated750 mg/1oralUnit Dose Services2008-03-01Not applicableUs
Nabumetonetablet, film coated750 mg/1oralGlenmark Pharmaceuticals Inc., Usa2008-03-01Not applicableUs
Nabumetonetablet750 mg/1oralAltura Pharmaceuticals, Inc.2010-01-01Not applicableUs
Nabumetonetablet500 mg/1oralREMEDYREPACK INC.2016-02-09Not applicableUs
Nabumetonetablet, film coated500 mg/1oralSTAT Rx USA LLC2008-03-01Not applicableUs
Nabumetonetablet, film coated750 mg/1oralAidarex Pharmaceuticals LLC2008-03-01Not applicableUs
Nabumetonetablet750 mg/1oralPd Rx Pharmaceuticals, Inc.2002-02-25Not applicableUs
Nabumetonetablet, film coated500 mg/1oralUnit Dose Services2008-03-01Not applicableUs
Nabumetonetablet, film coated500 mg/1oralGlenmark Pharmaceuticals Inc., Usa2008-03-01Not applicableUs
Nabumetonetablet500 mg/1oralAltura Pharmaceuticals, Inc.2010-01-01Not applicableUs
Nabumetonetablet750 mg/1oralMajor Pharmaceuticals2009-06-10Not applicableUs
Nabumetonetablet, film coated750 mg/1oralMylan Pharmaceuticals Inc.2012-08-21Not applicableUs
Nabumetonetablet, film coated750 mg/1oralAv Kare, Inc.2014-01-20Not applicableUs
Nabumetonetablet, film coated500 mg/1oralAidarex Pharmaceuticals LLC2011-06-13Not applicableUs
Nabumetonetablet, film coated500 mg/1oralCardinal Health2010-08-06Not applicableUs
Nabumetonetablet, film coated750 mg/1oralLake Erie Medical DBA Quality Care Products LLC2010-11-16Not applicableUs
Nabumetonetablet, film coated750 mg/1oralLupin Pharmaceuticals, Inc.2012-08-27Not applicableUs
Nabumetonetablet, film coated750 mg/1oralbryant ranch prepack2008-03-01Not applicableUs
Nabumetonetablet500 mg/1oralMajor Pharmaceuticals2009-06-10Not applicableUs
Nabumetonetablet, film coated500 mg/1oralMylan Pharmaceuticals Inc.2012-08-21Not applicableUs
Nabumetonetablet, film coated500 mg/1oralAv Kare, Inc.2014-01-20Not applicableUs
Nabumetonetablet, film coated750 mg/1oralRebel Distributors Corp.2008-03-01Not applicableUs
Nabumetonetablet, film coated750 mg/1oralPhysicians Total Care, Inc.2002-12-04Not applicableUs
Nabumetonetablet, film coated500 mg/1oralLake Erie Medical DBA Quality Care Products LLC2010-08-26Not applicableUs
Nabumetonetablet, film coated500 mg/1oralLupin Pharmaceuticals, Inc.2012-08-27Not applicableUs
Nabumetonetablet, film coated500 mg/1oralbryant ranch prepack2008-03-01Not applicableUs
Nabumetonetablet, film coated750 mg/1oralNcs Health Care Of Ky, Inc Dba Vangard Labs2010-01-22Not applicableUs
Nabumetonetablet750 mg/1oralEon Labs, Inc.2002-02-25Not applicableUs
Nabumetonetablet, film coated500 mg/1oralAmerican Health Packaging2010-10-012015-12-29Us
Nabumetonetablet, film coated500 mg/1oralLake Erie Medical & Surgical Supply DBA Quality Care Products LLC2011-06-13Not applicableUs
Nabumetonetablet, film coated500 mg/1oralRebel Distributors Corp.2008-03-01Not applicableUs
Nabumetonetablet, film coated500 mg/1oralPhysicians Total Care, Inc.2003-09-15Not applicableUs
Nabumetonetablet750 mg/1oralPar Pharmaceutical Inc2003-01-24Not applicableUs
Nabumetonetablet, film coated500 mg/1oralCarilion Materials Management2011-06-13Not applicableUs
Nabumetonetablet, film coated500 mg/1oralProficient Rx LP2008-03-01Not applicableUs
Nabumetonetablet, film coated500 mg/1oralNcs Health Care Of Ky, Inc Dba Vangard Labs2010-01-22Not applicableUs
Nabumetonetablet500 mg/1oralEon Labs, Inc.2002-02-25Not applicableUs
Nabumetonetablet, film coated750 mg/1oralExelan Pharmaceuticals Inc.2015-04-14Not applicableUs
Nabumetonetablet, film coated750 mg/1oralLake Erie Medical & Surgical Supply DBA Quality Care Products LLC2008-03-01Not applicableUs
Nabumetonetablet750 mg/1oralSTAT Rx USA LLC2003-01-24Not applicableUs
Nabumetonetablet, film coated750 mg/1oralH.J. Harkins Company, Inc.2008-03-01Not applicableUs
Nabumetonetablet500 mg/1oralPar Pharmaceutical Inc2003-01-24Not applicableUs
Nabumetonetablet, film coated750 mg/1oralAmerican Health Packaging2015-03-31Not applicableUs
Nabumetonetablet, film coated750 mg/1oralProficient Rx LP2011-06-13Not applicableUs
Nabumetonetablet, film coated500 mg/1oralNcs Health Care Of Ky, Inc Dba Vangard Labs2008-03-01Not applicableUs
Nabumetonetablet, film coated750 mg/1oralTeva Pharmaceuticals USA Inc2001-09-26Not applicableUs
Nabumetonetablet, film coated500 mg/1oralExelan Pharmaceuticals Inc.2015-04-14Not applicableUs
Approved Over the Counter ProductsNot Available
Unapproved/Other Products Not Available
International Brands
NameCompany
ArthaxanSmithKline Beecham (Germany; discontinued)
BalmoxBeecham (Portugal), Meda (Switzerland)
DolsinalFerrer (Spain; discontinued)
ListranUriach (Spain)
MebutanMeda (Netherlands)
NabuserGeymonat (Italy)
RelafenGlaxoSmithKline (Canada, USA; discontinued)
RelifMeda (Spain)
RelifenSanwa (Japan), GSK (South Africa)
RelifexMeda (Czeck Republic, Denmark, Finland, Germany, Greece, Hungary, Ireland, Italy, Norway, Sweden, United Kingdom), GSK (Israel, Mexico, Poland, Thailand, Turkey), SmithKline Beecham (Philippines)
Brand mixturesNot Available
SaltsNot Available
Categories
UNIILW0TIW155Z
CAS number42924-53-8
WeightAverage: 228.2863
Monoisotopic: 228.115029756
Chemical FormulaC15H16O2
InChI KeyInChIKey=BLXXJMDCKKHMKV-UHFFFAOYSA-N
InChI
InChI=1S/C15H16O2/c1-11(16)3-4-12-5-6-14-10-15(17-2)8-7-13(14)9-12/h5-10H,3-4H2,1-2H3
IUPAC Name
4-(6-methoxynaphthalen-2-yl)butan-2-one
SMILES
COC1=CC2=C(C=C1)C=C(CCC(C)=O)C=C2
Taxonomy
DescriptionThis compound belongs to the class of organic compounds known as naphthalenes. These are compounds containing a naphthalene moiety, which consists of two fused benzene rings.
KingdomOrganic compounds
Super ClassBenzenoids
ClassNaphthalenes
Sub ClassNot Available
Direct ParentNaphthalenes
Alternative Parents
Substituents
  • Naphthalene
  • Anisole
  • Alkyl aryl ether
  • Ketone
  • Ether
  • Hydrocarbon derivative
  • Organooxygen compound
  • Carbonyl group
  • Aromatic homopolycyclic compound
Molecular FrameworkAromatic homopolycyclic compounds
External Descriptors
Pharmacology
IndicationFor acute and chronic treatment of signs and symptoms of osteoarthritis and rheumatoid arthritis.
PharmacodynamicsNabumetone is a naphthylalkanone. Is is a non-selective prostaglandin G/H synthase (a.k.a. cyclooxygenase or COX) inhibitor that acts on both prostaglandin G/H synthase 1 and 2 (COX-1 and -2). Prostaglandin G/H synthase catalyzes the conversion of arachidonic acid to prostaglandin G2 and prostaglandin G2 to prostaglandin H2. Prostaglandin H2 is the precursor to a number of prostaglandins involved in fever, pain, swelling, inflammation, and platelet aggregation. The parent compound is a prodrug that undergoes hepatic biotransformation to the active compound, 6-methoxy-2-naphthylacetic acid (6MNA). The analgesic, antipyretic and anti-inflammatory effects of NSAIDs occur as a result of decreased prostaglandin synthesis.
Mechanism of actionThe parent compound is a prodrug, which undergoes hepatic biotransformation to the active component, 6-methoxy-2-naphthylacetic acid (6MNA), that is a potent inhibitor of prostaglandin synthesis, most likely through binding to the COX-2 and COX-1 receptors.
Related Articles
AbsorptionWell absorbed from the gastrointestinal tract. Coadministration of food increases the rate of absorption and subsequent appearance of 6MNA (the active metabolite) in the plasma but does not affect the extent of conversion of nabumetone into 6MNA.
Volume of distributionNot Available
Protein bindingThe active metabolite, 6MNA, is more than 99% bound to plasma proteins.
Metabolism

Undergoes rapid biotransformation to the principal active metabolite, 6-methoxy-2-naphthylacetic acid (6MNA). Approximately 35% of a 1000 mg oral dose of nabumetone is converted to 6MNA and 50% is converted into unidentified metabolites which are subsequently excreted in the urine.

SubstrateEnzymesProduct
Nabumetone
Not Available
6-methoxy-2-naphthylacetic acidDetails
Route of eliminationApproximately 35% of a 1000 mg oral dose of nabumetone is converted to 6MNA and 50% is converted into unidentified metabolites which are subsequently excreted in the urine.
Half lifeApproximately 23 hours for the active metabolite, 6MNA. Increased in patients with renal insufficiency.
Clearance
  • 20 – 30 mL/min
ToxicityThe one overdose occurred in a 17-year-old female patient who had a history of abdominal pain and was hospitalized for increased abdominal pain following ingestion of 30 nabumetone tablets (15 grams total). Stools were negative for occult blood and there was no fall in serum hemoglobin concentration. The patient had no other symptoms.
Affected organisms
  • Humans and other mammals
Pathways
PathwayCategorySMPDB ID
Nabumetone Action PathwayDrug actionSMP00114
SNP Mediated EffectsNot Available
SNP Mediated Adverse Drug ReactionsNot Available
ADMET
Predicted ADMET features
PropertyValueProbability
Human Intestinal Absorption+1.0
Blood Brain Barrier+0.9401
Caco-2 permeable+0.9049
P-glycoprotein substrateSubstrate0.5
P-glycoprotein inhibitor INon-inhibitor0.5653
P-glycoprotein inhibitor IIInhibitor0.5656
Renal organic cation transporterNon-inhibitor0.7143
CYP450 2C9 substrateNon-substrate0.7664
CYP450 2D6 substrateNon-substrate0.7329
CYP450 3A4 substrateSubstrate0.614
CYP450 1A2 substrateInhibitor0.959
CYP450 2C9 inhibitorNon-inhibitor0.9071
CYP450 2D6 inhibitorNon-inhibitor0.9231
CYP450 2C19 inhibitorNon-inhibitor0.8591
CYP450 3A4 inhibitorNon-inhibitor0.8235
CYP450 inhibitory promiscuityLow CYP Inhibitory Promiscuity0.6443
Ames testNon AMES toxic0.8942
CarcinogenicityNon-carcinogens0.8745
BiodegradationNot ready biodegradable0.8489
Rat acute toxicity1.7384 LD50, mol/kg Not applicable
hERG inhibition (predictor I)Weak inhibitor0.7536
hERG inhibition (predictor II)Non-inhibitor0.8059
ADMET data is predicted using admetSAR, a free tool for evaluating chemical ADMET properties. (23092397 )
Pharmacoeconomics
Manufacturers
  • Actavis elizabeth llc
  • Copley pharmaceutical inc
  • Dr reddys laboratories ltd
  • Invagen pharmaceuticals inc
  • Matrix laboratories ltd
  • Par pharmaceutical
  • Sandoz inc
  • Teva pharmaceuticals usa inc
  • Smithkline beecham corp dba glaxosmithkline
Packagers
Dosage forms
FormRouteStrength
Tabletoral500 mg
Tabletoral500 mg/1
Tabletoral750 mg/1
Tablet, film coatedoral500 mg/1
Tablet, film coatedoral750 mg/1
Tabletoral750 mg
Prices
Unit descriptionCostUnit
Relafen 750 mg tablet2.91USD tablet
Relafen 500 mg tablet2.82USD tablet
Nabumetone 750 mg tablet1.56USD tablet
Nabumetone 500 mg tablet1.32USD tablet
Apo-Nabumetone 500 mg Tablet0.39USD tablet
Mylan-Nabumetone 500 mg Tablet0.39USD tablet
Novo-Nabumetone 500 mg Tablet0.39USD tablet
DrugBank does not sell nor buy drugs. Pricing information is supplied for informational purposes only.
PatentsNot Available
Properties
StateSolid
Experimental Properties
PropertyValueSource
water solubilityPractically insolubleNot Available
logP3.08ADLARD,M ET AL. (1995)
Predicted Properties
PropertyValueSource
Water Solubility0.00193 mg/mLALOGPS
logP3.41ALOGPS
logP3.22ChemAxon
logS-5.1ALOGPS
pKa (Strongest Acidic)19.59ChemAxon
pKa (Strongest Basic)-4.8ChemAxon
Physiological Charge0ChemAxon
Hydrogen Acceptor Count2ChemAxon
Hydrogen Donor Count0ChemAxon
Polar Surface Area26.3 Å2ChemAxon
Rotatable Bond Count4ChemAxon
Refractivity68.43 m3·mol-1ChemAxon
Polarizability26.17 Å3ChemAxon
Number of Rings2ChemAxon
Bioavailability1ChemAxon
Rule of FiveYesChemAxon
Ghose FilterYesChemAxon
Veber's RuleYesChemAxon
MDDR-like RuleYesChemAxon
Spectra
Mass Spec (NIST)Not Available
SpectraNot Available
References
Synthesis Reference

Brian F. Becnel, Mahmood Sabahi, Kevin J. Theriot, “Production of nabumetone or precursors thereof.” U.S. Patent US5907069, issued December, 1985.

US5907069
General ReferencesNot Available
External Links
ATC CodesM01AX01
AHFS Codes
  • 28:08.04.92
PDB EntriesNot Available
FDA labelDownload (322 KB)
MSDSDownload (29.8 KB)
Interactions
Drug Interactions
Drug
AbciximabNabumetone may increase the anticoagulant activities of Abciximab.
AcenocoumarolNabumetone may increase the anticoagulant activities of Acenocoumarol.
Acetylsalicylic acidThe risk or severity of adverse effects can be increased when Nabumetone is combined with Acetylsalicylic acid.
AliskirenNabumetone may decrease the antihypertensive activities of Aliskiren.
AlteplaseNabumetone may increase the anticoagulant activities of Alteplase.
AmikacinNabumetone may decrease the excretion rate of Amikacin which could result in a lower serum level and potentially a reduction in efficacy.
AmitriptylineAmitriptyline may increase the antiplatelet activities of Nabumetone.
AnistreplaseNabumetone may increase the anticoagulant activities of Anistreplase.
ApixabanThe risk or severity of adverse effects can be increased when Nabumetone is combined with Apixaban.
ArbekacinNabumetone may decrease the excretion rate of Arbekacin which could result in a lower serum level and potentially a reduction in efficacy.
BalsalazideNabumetone may increase the nephrotoxic activities of Balsalazide.
Citric AcidNabumetone may increase the anticoagulant activities of Citric Acid.
ColesevelamColesevelam can cause a decrease in the absorption of Nabumetone resulting in a reduced serum concentration and potentially a decrease in efficacy.
CollagenaseThe risk or severity of adverse effects can be increased when Nabumetone is combined with Collagenase.
CyclosporineNabumetone may increase the nephrotoxic activities of Cyclosporine.
Dabigatran etexilateNabumetone may increase the anticoagulant activities of Dabigatran etexilate.
DalteparinNabumetone may increase the anticoagulant activities of Dalteparin.
DasatinibDasatinib may increase the anticoagulant activities of Nabumetone.
DeferasiroxThe risk or severity of adverse effects can be increased when Nabumetone is combined with Deferasirox.
Deoxycholic AcidThe risk or severity of adverse effects can be increased when Nabumetone is combined with Deoxycholic Acid.
DesmopressinThe risk or severity of adverse effects can be increased when Nabumetone is combined with Desmopressin.
DexketoprofenThe risk or severity of adverse effects can be increased when Dexketoprofen is combined with Nabumetone.
DiclofenacThe risk or severity of adverse effects can be increased when Diclofenac is combined with Nabumetone.
DicoumarolNabumetone may increase the anticoagulant activities of Dicoumarol.
DigoxinThe serum concentration of Digoxin can be increased when it is combined with Nabumetone.
DrospirenoneNabumetone may increase the hyperkalemic activities of Drospirenone.
Edetic AcidNabumetone may increase the anticoagulant activities of Edetic Acid.
EnoxaparinNabumetone may increase the anticoagulant activities of Enoxaparin.
EplerenoneNabumetone may decrease the antihypertensive activities of Eplerenone.
Ethyl biscoumacetateNabumetone may increase the anticoagulant activities of Ethyl biscoumacetate.
FloctafenineThe risk or severity of adverse effects can be increased when Floctafenine is combined with Nabumetone.
FludrocortisoneThe risk or severity of adverse effects can be increased when Fludrocortisone is combined with Nabumetone.
Fondaparinux sodiumNabumetone may increase the anticoagulant activities of Fondaparinux sodium.
FramycetinNabumetone may decrease the excretion rate of Framycetin which could result in a lower serum level and potentially a reduction in efficacy.
GentamicinNabumetone may decrease the excretion rate of Gentamicin which could result in a lower serum level and potentially a reduction in efficacy.
GlucosamineGlucosamine may increase the antiplatelet activities of Nabumetone.
HaloperidolThe risk or severity of adverse effects can be increased when Nabumetone is combined with Haloperidol.
HeparinNabumetone may increase the anticoagulant activities of Heparin.
HomoharringtonineThe risk or severity of adverse effects can be increased when Nabumetone is combined with Homoharringtonine.
HydralazineNabumetone may decrease the antihypertensive activities of Hydralazine.
Ibritumomab tiuxetanThe risk or severity of adverse effects can be increased when Nabumetone is combined with Ibritumomab.
IbrutinibThe risk or severity of adverse effects can be increased when Ibrutinib is combined with Nabumetone.
IcosapentThe risk or severity of adverse effects can be increased when Nabumetone is combined with Icosapent.
InfliximabThe risk or severity of adverse effects can be increased when Infliximab is combined with Nabumetone.
KanamycinNabumetone may decrease the excretion rate of Kanamycin which could result in a lower serum level and potentially a reduction in efficacy.
KetorolacThe risk or severity of adverse effects can be increased when Ketorolac is combined with Nabumetone.
LimaprostLimaprost may increase the antiplatelet activities of Nabumetone.
LithiumThe serum concentration of Lithium can be increased when it is combined with Nabumetone.
MethotrexateThe serum concentration of Methotrexate can be increased when it is combined with Nabumetone.
MorniflumateThe risk or severity of adverse effects can be increased when Morniflumate is combined with Nabumetone.
NadololNabumetone may decrease the antihypertensive activities of Nadolol.
NeomycinNabumetone may decrease the excretion rate of Neomycin which could result in a lower serum level and potentially a reduction in efficacy.
NetilmicinNabumetone may decrease the excretion rate of Netilmicin which could result in a lower serum level and potentially a reduction in efficacy.
ObinutuzumabThe risk or severity of adverse effects can be increased when Nabumetone is combined with Obinutuzumab.
Omega-3 fatty acidsOmega-3 fatty acids may increase the antiplatelet activities of Nabumetone.
PamidronateThe risk or severity of adverse effects can be increased when Nabumetone is combined with Pamidronate.
ParoxetineParoxetine may increase the antiplatelet activities of Nabumetone.
PemetrexedThe serum concentration of Pemetrexed can be increased when it is combined with Nabumetone.
Pentosan PolysulfateThe risk or severity of adverse effects can be increased when Pentosan Polysulfate is combined with Nabumetone.
PentoxifyllinePentoxifylline may increase the antiplatelet activities of Nabumetone.
PerindoprilThe risk or severity of adverse effects can be increased when Perindopril is combined with Nabumetone.
PhenindioneNabumetone may increase the anticoagulant activities of Phenindione.
PhenprocoumonNabumetone may increase the anticoagulant activities of Phenprocoumon.
PorfimerNabumetone may increase the photosensitizing activities of Porfimer.
PralatrexateThe serum concentration of Pralatrexate can be increased when it is combined with Nabumetone.
ProbenecidThe serum concentration of Nabumetone can be increased when it is combined with Probenecid.
ReteplaseNabumetone may increase the anticoagulant activities of Reteplase.
RibostamycinNabumetone may decrease the excretion rate of Ribostamycin which could result in a lower serum level and potentially a reduction in efficacy.
RidogrelNabumetone may increase the anticoagulant activities of Ridogrel.
RivaroxabanNabumetone may increase the anticoagulant activities of Rivaroxaban.
SparfloxacinNabumetone may increase the neuroexcitatory activities of Sparfloxacin.
SpectinomycinNabumetone may decrease the excretion rate of Spectinomycin which could result in a lower serum level and potentially a reduction in efficacy.
StreptokinaseNabumetone may increase the anticoagulant activities of Streptokinase.
StreptomycinNabumetone may decrease the excretion rate of Streptomycin which could result in a lower serum level and potentially a reduction in efficacy.
SulodexideNabumetone may increase the anticoagulant activities of Sulodexide.
TacrolimusNabumetone may increase the nephrotoxic activities of Tacrolimus.
TalniflumateThe risk or severity of adverse effects can be increased when Talniflumate is combined with Nabumetone.
TenecteplaseNabumetone may increase the anticoagulant activities of Tenecteplase.
TenofovirThe risk or severity of adverse effects can be increased when Nabumetone is combined with Tenofovir.
TipranavirTipranavir may increase the antiplatelet activities of Nabumetone.
TobramycinNabumetone may decrease the excretion rate of Tobramycin which could result in a lower serum level and potentially a reduction in efficacy.
TorasemideNabumetone may decrease the diuretic activities of Torasemide.
TositumomabThe risk or severity of adverse effects can be increased when Nabumetone is combined with Tositumomab.
TreprostinilThe risk or severity of adverse effects can be increased when Treprostinil is combined with Nabumetone.
TriamtereneNabumetone may decrease the antihypertensive activities of Triamterene.
TrichlormethiazideThe therapeutic efficacy of Trichlormethiazide can be decreased when used in combination with Nabumetone.
UnoprostoneThe therapeutic efficacy of Unoprostone can be decreased when used in combination with Nabumetone.
UrokinaseNabumetone may increase the anticoagulant activities of Urokinase.
ValsartanThe risk or severity of adverse effects can be increased when Valsartan is combined with Nabumetone.
VancomycinThe serum concentration of Vancomycin can be increased when it is combined with Nabumetone.
VenlafaxineVenlafaxine may increase the antiplatelet activities of Nabumetone.
VerteporfinNabumetone may increase the photosensitizing activities of Verteporfin.
Vitamin EVitamin E may increase the antiplatelet activities of Nabumetone.
WarfarinNabumetone may increase the anticoagulant activities of Warfarin.
Food Interactions
  • Avoid alcohol.
  • Take with food for faster absorption.

Targets

Kind
Protein
Organism
Human
Pharmacological action
yes
Actions
inhibitor
General Function:
Prostaglandin-endoperoxide synthase activity
Specific Function:
Converts arachidonate to prostaglandin H2 (PGH2), a committed step in prostanoid synthesis. Constitutively expressed in some tissues in physiological conditions, such as the endothelium, kidney and brain, and in pathological conditions, such as in cancer. PTGS2 is responsible for production of inflammatory prostaglandins. Up-regulation of PTGS2 is also associated with increased cell adhesion, p...
Gene Name:
PTGS2
Uniprot ID:
P35354
Molecular Weight:
68995.625 Da
References
  1. Fackovcova D, Kristova V, Kriska M: Renal damage induced by the treatment with non-opioid analgesics--theoretical assumption or clinical significance. Bratisl Lek Listy. 2000;101(8):417-22. [PubMed:11153163 ]
  2. Roy HK, Karolski WJ, Ratashak A: Distal bowel selectivity in the chemoprevention of experimental colon carcinogenesis by the non-steroidal anti-inflammatory drug nabumetone. Int J Cancer. 2001 May 15;92(4):609-15. [PubMed:11304699 ]
  3. van Kraaij DJ, Hovestad-Witterland AH, de Metz M, Vollaard EJ: A comparison of the effects of nabumetone vs meloxicam on serum thromboxane B2 and platelet function in healthy volunteers. Br J Clin Pharmacol. 2002 Jun;53(6):644-7. [PubMed:12047490 ]
  4. Hedner T, Samulesson O, Wahrborg P, Wadenvik H, Ung KA, Ekbom A: Nabumetone: therapeutic use and safety profile in the management of osteoarthritis and rheumatoid arthritis. Drugs. 2004;64(20):2315-43; discussion 2344-5. [PubMed:15456329 ]
  5. Elliott SN, McKnight W, Cirino G, Wallace JL: A nitric oxide-releasing nonsteroidal anti-inflammatory drug accelerates gastric ulcer healing in rats. Gastroenterology. 1995 Aug;109(2):524-30. [PubMed:7615202 ]
  6. Chen X, Ji ZL, Chen YZ: TTD: Therapeutic Target Database. Nucleic Acids Res. 2002 Jan 1;30(1):412-5. [PubMed:11752352 ]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
inhibitor
General Function:
Prostaglandin-endoperoxide synthase activity
Specific Function:
Converts arachidonate to prostaglandin H2 (PGH2), a committed step in prostanoid synthesis. Involved in the constitutive production of prostanoids in particular in the stomach and platelets. In gastric epithelial cells, it is a key step in the generation of prostaglandins, such as prostaglandin E2 (PGE2), which plays an important role in cytoprotection. In platelets, it is involved in the gener...
Gene Name:
PTGS1
Uniprot ID:
P23219
Molecular Weight:
68685.82 Da
References
  1. Giuliano F, Ferraz JG, Pereira R, de Nucci G, Warner TD: Cyclooxygenase selectivity of non-steroid anti-inflammatory drugs in humans: ex vivo evaluation. Eur J Pharmacol. 2001 Aug 24;426(1-2):95-103. [PubMed:11525777 ]
  2. Takeuchi K, Smale S, Premchand P, Maiden L, Sherwood R, Thjodleifsson B, Bjornsson E, Bjarnason I: Prevalence and mechanism of nonsteroidal anti-inflammatory drug-induced clinical relapse in patients with inflammatory bowel disease. Clin Gastroenterol Hepatol. 2006 Feb;4(2):196-202. [PubMed:16469680 ]
  3. Cipollone F, Ganci A, Panara MR, Greco A, Cuccurullo F, Patrono C, Patrignani P: Effects of nabumetone on prostanoid biosynthesis in humans. Clin Pharmacol Ther. 1995 Sep;58(3):335-41. [PubMed:7554708 ]
  4. Bensen W, Zizzo A: Newer, safer nonsteroidal anti-inflammatory drugs. Rational NSAID selection for arthritis. Can Fam Physician. 1998 Jan;44:101-2, 105-7. [PubMed:9481468 ]

Enzymes

Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
inhibitor
General Function:
Peroxidase activity
Specific Function:
Part of the host defense system of polymorphonuclear leukocytes. It is responsible for microbicidal activity against a wide range of organisms. In the stimulated PMN, MPO catalyzes the production of hypohalous acids, primarily hypochlorous acid in physiologic situations, and other toxic intermediates that greatly enhance PMN microbicidal activity.
Gene Name:
MPO
Uniprot ID:
P05164
Molecular Weight:
83867.71 Da
References
  1. Saleh TS, Calixto JB, Medeiros YS: Effects of anti-inflammatory drugs upon nitrate and myeloperoxidase levels in the mouse pleurisy induced by carrageenan. Peptides. 1999;20(8):949-56. [PubMed:10503773 ]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
substrate
General Function:
Oxidoreductase activity, acting on paired donors, with incorporation or reduction of molecular oxygen, reduced flavin or flavoprotein as one donor, and incorporation of one atom of oxygen
Specific Function:
Cytochromes P450 are a group of heme-thiolate monooxygenases. In liver microsomes, this enzyme is involved in an NADPH-dependent electron transport pathway. It oxidizes a variety of structurally unrelated compounds, including steroids, fatty acids, and xenobiotics. Most active in catalyzing 2-hydroxylation. Caffeine is metabolized primarily by cytochrome CYP1A2 in the liver through an initial N...
Gene Name:
CYP1A2
Uniprot ID:
P05177
Molecular Weight:
58293.76 Da
References
  1. Turpeinen M, Hofmann U, Klein K, Murdter T, Schwab M, Zanger UM: A predominate role of CYP1A2 for the metabolism of nabumetone to the active metabolite, 6-methoxy-2-naphthylacetic acid, in human liver microsomes. Drug Metab Dispos. 2009 May;37(5):1017-24. doi: 10.1124/dmd.108.025700. Epub 2009 Feb 9. [PubMed:19204080 ]
Comments
comments powered by Disqus
Drug created on June 13, 2005 07:24 / Updated on September 16, 2013 17:10